Italy Fines Apple €98.6 Million Over App Store Dominance 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
HAYWARD, Calif., Sept. 05, 2017 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, today announced its participation in the Citi 12th Annual Biotech Conference. Anthera will host meetings at the Citi Biotech Conference in Boston on Thursday, September 7th.
Additional information on Anthera can be found at www.anthera.com
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
Contact Information CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc. [email protected] For Media Inquiries: Srikant Ramaswami rbb Communications [email protected] 718-710-1350
